Northwest & Ethical Investments L.P. Has $425,000 Holdings in ADMA Biologics Inc $ADMA

Northwest & Ethical Investments L.P. increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 143.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,400 shares of the biotechnology company’s stock after acquiring an additional 13,800 shares during the period. Northwest & Ethical Investments L.P.’s holdings in ADMA Biologics were worth $425,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ADMA. Amalgamated Bank increased its holdings in ADMA Biologics by 0.8% during the 2nd quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company’s stock worth $1,232,000 after purchasing an additional 540 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 0.3% in the second quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company’s stock valued at $4,051,000 after purchasing an additional 571 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock worth $1,002,000 after buying an additional 670 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ADMA Biologics by 1.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 711 shares in the last quarter. Finally, Blue Trust Inc. raised its position in ADMA Biologics by 53.6% in the 2nd quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 964 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $19.12 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The stock’s 50-day simple moving average is $15.56 and its 200 day simple moving average is $17.30. The company has a market cap of $4.55 billion, a P/E ratio of 22.23 and a beta of 0.40. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $134.22 million during the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 earnings per share. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.